Stock Pick

Category: Stock Market

  • Is Cytosorbents’ (NASDAQ:CTSO) Share Price Gain Of 133% Well Earned?

    Is Cytosorbents' (NASDAQ:CTSO) Share Price Gain Of 133% Well Earned?It might seem bad, but the worst that can happen when you buy a stock (without leverage) is that its share price goes…

    from Yahoo Finance https://ift.tt/32E73qb

  • Coca-Cola revenue tumbles as lockdowns hammer soda sales

    Coca-Cola revenue tumbles as lockdowns hammer soda salesThe Diet Coke, Fanta and Sprite maker generates about half of its revenues by selling its soft drinks and concentrates to restaurants and theater operators, such as McDonald’s Corp and AMC Entertainment Holdings Inc, but most of them had to close some or all of their operations under government-mandated curbs to fight the health crisis. “We believe the second quarter will prove to be the most challenging of the year; however, we still have work to do,” Chief Executive Officer James Quincey said in a statement. Unit volume, a key measure that indicates demand, declined 16%, with Coca-Cola falling 7% and sparkling soft drinks tumbling 12%.

    from Yahoo Finance https://ift.tt/2ZL0wIg

  • Suspect In Slaying Of Federal Judge’s Son Was An M7 MBA

    Suspect In Slaying Of Federal Judge’s Son Was An M7 MBARoy Den Hollander was found dead two hours from the site of the New Jersey attackThe post Suspect In Slaying Of Federal Judge's Son Was An M7 MBA appeared first on Poets&Quants.

    from Yahoo Finance https://ift.tt/2E3jGkk

  • IBM CEO: ‘The trend we see in the market is clear’

    IBM CEO: 'The trend we see in the market is clear'IBM has jettisoned some of its legacy business to focus on the high-margin cloud computing business, an area that has seen a lot of action in recent years as companies ramp up their digital shift to boost efficiency. Revenue from the cloud business, previously headed by Krishna, rose 30% to $6.3 billion in the second quarter. Krishna took over as chief executive officer from Ginni Rometty in April, while appointing former Bank of America Corp's top technology executive, Howard Boville, as the new head of the cloud business.

    from Yahoo Finance https://ift.tt/3eHyzp6

  • Word on the street: Democrats push for elimination of SALT deduction cap

    Word on the street: Democrats push for elimination of SALT deduction capYahoo Finance’s On the Move panel discuss the latest headline making news stories.

    from Yahoo Finance https://ift.tt/3hjhYcL

  • It’s Silver’s Turn to Shine as Prices Surge to Four-Year High

    It’s Silver’s Turn to Shine as Prices Surge to Four-Year High(Bloomberg) — Silver is hitting its sweet spot. While viewed as a haven from market turmoil — just like pricier sister gold — silver also has wide industrial uses in products like solar panels and electronics. That means the metal’s drawing both investors worried about rising virus cases and those focused on rosier indicators, from optimism over China’s recovery and promising vaccine news, to the landmark stimulus package clinched by Europe’s leaders.Read more about what’s moving global markets todaySpot silver powered through $20 an ounce Tuesday and is trading near a four-year high. The cheaper metal has outpaced gold’s own gains this month, and holdings in silver-backed exchange-traded funds have increased for 12 straight weeks to a record.“Silver is now leading the charge,” said Stephen Innes, chief market strategist at AxiCorp Ltd. The metal is following the same trajectory as during the global financial crisis, he said. Back then, prices dropped during the worst of the crisis before rallying to fresh records near $50 by 2011.Spot silver jumped as much as 3.3% on Tuesday to $20.5609 an ounce, the highest since August 2016, extending this year’s gains to 15%. Futures in New York, which breached the $20 level on Monday, rose as high as $20.945 an ounce. Other precious metals also advanced as the dollar weakened, with spot gold adding 0.5% to $1,827.20 an ounce, the highest since September 2011.Read also: Gold’s Good But Silver’s Super as Bulls Go on the RampageEven after recent gains, there’s a long list of banks and traders predicting silver will keep rising as investors continue to pile in. Citigroup Inc. said in a report this week that it sees prices rising to $25 in the next six to 12 months, with the potential for $30 based on the bank’s bull case.For more articles like this, please visit us at bloomberg.comSubscribe now to stay ahead with the most trusted business news source.©2020 Bloomberg L.P.

    from Yahoo Finance https://ift.tt/3fMgs2I

  • More than 50% of market pros think a vaccine will be ready within a year: Morning Brief

    More than 50% of market pros think a vaccine will be ready within a year: Morning BriefTop news and what to watch in the markets on Tuesday, July 21, 2020.

    from Yahoo Finance https://ift.tt/3fOMbAi

  • Investor Optimism Abounds Accenture plc (NYSE:ACN) But Growth Is Lacking

    Investor Optimism Abounds Accenture plc (NYSE:ACN) But Growth Is LackingAccenture plc's (NYSE:ACN) price-to-earnings (or "P/E") ratio of 28.5x might make it look like a strong sell right now…

    from Yahoo Finance https://ift.tt/3eMNNt0

  • Why the Pantoro share price soared 17% today

    gold mining

    The Pantoro Ltd (ASX: PNR) share price soared 17.39% higher today to close trade at 27 cents per share. This positive share price action came after Pantoro announced this morning that it had encountered high grade mineralisation in its maiden drilling campaign at the Sailfish prospect on Lake Cowan.

    What does Pantoro do?

    Pantoro is an Australian gold producer. The company’s Halls Creek gold project in the Kimberley region of Western Australia is its key operational focus. The project provides Pantoro with a platform for growth through the operation of its first producing gold asset and includes underground and open pit mines, and a modern processing facility.

    Why did the Pantoro share price storm higher today?

    Pantoro announced very high grade mineralisation was encountered in its maiden drilling campaign on Lake Cowan. These finds demonstrated the sheer potential of the site, with the potential for more high grade finds in the future. Some of the key highlights were as follows:

    • Drilling returned 8.1 m @ 67.29 g/t Au from 78.6 m down hole
    • The intersection included 0.7 m @ 521 g/t and 0.25 m @ 252g/t Au.
    • Other significant intercepts include 1.8 m @ 4.25 g/t Au, and 3.5 m @ 2.56g/t Au.
    • Confirms historical intersection of 1.5 m @ 461.47 gt/Au, drilled by Western Mining in 1992

    Commenting on the results, Pantoro managing director Paul Cmrlec said: “These results from our initial eight diamond drillhole program at the Sailfish prospect on Lake Cowan highlights the immense exploration potential of the project, and in particular the likely presence of further very high grade mineralisation that Norseman has been known for over many decades.”

    What now for the Pantoro share price

    Whilst the discoveries are excellent news, the company advises the exploration is in very early stages and so it is too early to speculate what the results may mean in the context of the broader project. Nonetheless, the results are definitely a positive for Pantoro.

    Pantoro has seen a strong resurgence in its share price this year, climbing almost 280% since its lows in March. The Pantoro share price is up 63% since this time last year, and the company’s market capitalisation is currently sitting around the $270 million mark. 

    Where to invest $1,000 right now

    When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for more than eight years has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

    Scott just revealed what he believes are the five best ASX stocks for investors to buy right now. These stocks are trading at dirt-cheap prices and Scott thinks they are great buys right now.

    See The 5 Stocks

    *Returns as of June 30th

    More reading

    Motley Fool contributor Daniel Ewing has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

    The post Why the Pantoro share price soared 17% today appeared first on Motley Fool Australia.

    from Motley Fool Australia https://ift.tt/2BlU1lW

  • Acadia Plunges 12% As Depressive Study Misses Goals; Analyst Says Buy

    Acadia Plunges 12% As Depressive Study Misses Goals; Analyst Says BuyShares in Acadia Pharmaceuticals (ACAD) plunged 12% in Monday’s extended trading, after the company announced disappointing top-line results from its 298 patient Phase 3 CLARITY study evaluating pimavanserin as an adjunctive treatment for major depressive disorder (MDD).The study did not achieve statistical significance on the primary endpoint which was the 17-item Hamilton Depression Rating Scale (HAMD-17) total score change from baseline to week 5. Pimavanserin 34 mg, given once-daily as an adjunctive treatment to standard antidepressant therapy was associated with a mean reduction of 9.0 in HAMD-17 total score compared to 8.1 for placebo as an adjunctive treatment (p=0.296).Positive results were observed on the key secondary endpoint, the Clinical Global Impression – Severity (CGI-S) score, a clinician assessment of a patient’s severity of depression (nominal p=0.042) and on the Karolinska Sleepiness Scale (KSS) score (nominal p=0.005).“We observed a consistent improvement of depressive symptoms over time with pimavanserin but, unfortunately, the robust positive results from our CLARITY-1 study were not replicated,” said Serge Stankovic, ACADIA’s President. “While these results do not support the product profile to pursue an additional Phase 3 study in adjunctive MDD, we will continue to analyze the data and the findings from our earlier positive depression studies as we assess next steps.”In the study, pimavanserin was generally well-tolerated when added to existing antidepressant therapy, and similar rates of adverse events were observed between pimavanserin (58.1%) and placebo (54.7%).However, on a more positive note, the company also announced that the FDA accepted Nuplazid’s (pimavanserin) supplemental new drug application (sNDA) for dementia-related psychosis (DRP). The PDUFA date for the FDA’s decision is set for April 3, 2021.“Nuplazid’s Phase 3 failure in major depressive disorder (MDD) is certainly disappointing but not entirely surprising given how difficult a nut this indication is to crack” commented JP Morgan analyst Cory Kasimov following the update.However he remains bullish on ACAD’s longer-term outlook and the DRP indication specifically. “We remain highly confident in the approvability of DRP” the analyst commented. He has a buy rating on the stock and $66 price target (19% upside potential).Shares in ACAD are up 30% year-to-date, and the stock shows a bullish Strong Buy analyst consensus. That’s with an average analyst price target of $60 (8% upside potential). (See ACAD stock analysis on TipRanks)Related News: Pfizer, BioNTech Ink UK Supply Deal For 30M Covid-19 Vaccine Doses NuVasive Spikes 5% After-Hours On Sharp Procedure Rebound GSK Buys 10% Stake In Germany’s CureVac To Develop mRNA Vaccines More recent articles from Smarter Analyst: * IBM Pops 5% in Extended Trading After Quarterly Profit Beats Expectations * NuVasive Spikes 5% After-Hours On Sharp Procedure Rebound * Apple iPhone SE Boosts Q2, But Unlikely To Cannibalize 5G Sales – Report * Is Nokia Stock a Buy Right Now? This Is What You Need to Know

    from Yahoo Finance https://ift.tt/2E5Cnnx